Clinical Trial Update: N-803 Maintenance Therapy Post CAR T-cell Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating N-803 as maintenance therapy after CAR T-cell treatment in relapsed or refractory B-cell non-Hodgkin lymphoma has been withd…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• N-803

Snippet

Sponsor: University of Utah | Conditions: B-cell Non Hodgkin Lymphoma | Phase 1 | Status: WITHDRAWN